Biographical Sketch
Kamal R. Chémali, MD, is Staff Neurologist at Cleveland Clinic and is board-certified by the American Board of Psychiatry and Neurology and American Board of Electrodiagnostic Medicine. Treatment interests include autonomic nervous system disorders, complex regional pain syndrome (reflex sympathetic dystrophy), painful peripheral neuropathies and music therapy.
Specialty Interests
autonomic disorders, autonomic nervous system diseases and testing, Clinical Trials, Electromyography, EMG, inherited and demyelinating neuropathies, music therapy and music and the brain research, Myasthenia Gravis, neuroimaging, Neuromuscular diseases, Peripheral Neuropathy
Innovations & Patents
Pioneered the use of infrared dynamic pupillometry in the diagnosis of small-fiber neuropathy and myasthenia gravis. Built a special pupillometer with the manufacturer (PMI) specifically designed to diagnose these disorders. The potential benefit for patients is that this is a simple, quick and painless neurophysiological test.
Industry Relationships
Cleveland Clinic physicians and scientists report if they
have any collaborations with the pharmaceutical or medical
device industries as part of the Cleveland Clinic’s
procedures. The Cleveland Clinic publicly discloses
payments to its physicians and scientists for speaking and
consulting of $5,000 or more per year, and any equity,
royalties, and fiduciary relationships in companies with
which they collaborate. In publicly disclosing this
information, the Cleveland Clinic tries to provide
information as accurately as possible about its doctors’
connections with industry and those of their immediate
family members. As of 10/5/2008,
Dr. Chemali has reported no financial relationship with
industry that is applicable to this listing. Patients
should feel free to contact their doctor about
relationships with industry and how the relationships are
overseen by the Cleveland Clinic. To learn more about
the Cleveland Clinic’s policies on collaborations with
industry and innovation management, go to our
Integrity in Innovation page.
